Rhumbline Advisers Bio N Tech Se Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Bio N Tech Se stock. As of the latest transaction made, Rhumbline Advisers holds 120 shares of BNTX stock, worth $14,486. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120
Previous 120
-0.0%
Holding current value
$14,486
Previous $9,000
55.56%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BNTX
# of Institutions
357Shares Held
38.3MCall Options Held
2.45MPut Options Held
2.29M-
Baillie Gifford & CO8.31MShares$1 Billion0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.52MShares$545 Million0.4% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.36MShares$526 Million2.05% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$229 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$218 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $29.3B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...